Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trial.

Frontiers in cardiovascular medicine·2026

Same author

Clinical-Pharmacological Drug Information Center of Hannover Medical School: Update From a Tertiary Care University Hospital (2022-2024).

Pharmacology research & perspectives·2026

Same author

Human vs. artificial intelligence: Physicians outperform ChatGPT in real-world pharmacotherapy counselling.

British journal of clinical pharmacology·2025

Same author

[Severe late-onset neutropenia after rituximab administration].

Zeitschrift fur Rheumatologie·2025

Same author

Therapeutic Drug Monitoring of Nirmatrelvir/Ritonavir (Paxlovid) in Patients Treated for COVID-19: Results From a Prospective Multicenter Observational Study.

Therapeutic drug monitoring·2024

Same author

The Implementation of a Pretomanid-Based Treatment Regimen for Multidrug-Resistant Tuberculosis: A Case Series.

Deutsches Arzteblatt international·2023

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

[Creatine kinase increase under simvastatin--therapeutic consequences?].

Celine C Rasche-Schürmann¹, Gesine Picksak, Dirk O Stichtenoth

¹Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1,30625 Hannover.

Medizinische Monatsschrift Fur Pharmazeuten

|June 5, 2008

Summary

This summary is machine-generated.

Statin-induced myopathy, a serious side effect, presents with muscle pain and weakness. Discontinue statin therapy if symptoms appear or creatine kinase (CK) levels exceed five times the normal limit.

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Area of Science:

Pharmacology
Clinical Medicine
Toxicology

Context:

Statins are widely prescribed cholesterol-lowering drugs.
Myopathy is a significant dose-dependent adverse effect of statin therapy.
Rhabdomyolysis and death are potential severe outcomes.

Purpose:

To outline the clinical presentation and management of statin-induced myopathy.
To provide guidance on monitoring creatine kinase (CK) levels.
To inform clinical decisions regarding statin discontinuation or continuation.

Summary:

Statin-induced myopathy is characterized by muscle pain, weakness, and elevated serum creatine kinase (CK).
Discontinuation of statin therapy is recommended if myopathy symptoms are present or CK levels are >5 times the upper limit of normal.
Asymptomatic CK elevations below this threshold allow for continued therapy with monitoring.

Impact:

Facilitates timely diagnosis and management of statin-induced myopathy.
Aims to prevent severe complications such as rhabdomyolysis.
Supports evidence-based clinical practice for statinPrescribing.